Denali Advisors LLC Takes Position in Cencora, Inc. (NYSE:COR)

Denali Advisors LLC purchased a new position in shares of Cencora, Inc. (NYSE:COR) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 1,600 shares of the company’s stock, valued at approximately $389,000.

A number of other hedge funds have also added to or reduced their stakes in the company. Fisher Asset Management LLC bought a new position in shares of Cencora in the 4th quarter valued at $244,000. Trust Co. of Vermont acquired a new position in Cencora during the fourth quarter worth about $62,000. Wahed Invest LLC acquired a new position in Cencora during the fourth quarter worth about $567,000. Vanguard Group Inc. bought a new position in shares of Cencora in the fourth quarter worth about $4,212,508,000. Finally, Hennessy Advisors Inc. acquired a new stake in shares of Cencora in the 4th quarter valued at approximately $3,307,000. 97.52% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

COR has been the subject of several research reports. Robert W. Baird increased their price objective on shares of Cencora from $275.00 to $277.00 and gave the company an “outperform” rating in a research note on Thursday, May 2nd. StockNews.com cut Cencora from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 2nd. Citigroup boosted their price objective on Cencora from $265.00 to $280.00 and gave the stock a “buy” rating in a research report on Tuesday, April 30th. Finally, SVB Leerink reiterated an “outperform” rating and issued a $275.00 target price on shares of Cencora in a research report on Thursday, June 27th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $235.30.

Cencora Stock Down 0.0 %

Shares of COR opened at $222.50 on Thursday. The company has a market capitalization of $44.38 billion, a PE ratio of 24.34, a PEG ratio of 1.57 and a beta of 0.45. The stock’s 50-day moving average price is $228.24 and its two-hundred day moving average price is $228.43. The company has a current ratio of 0.89, a quick ratio of 0.53 and a debt-to-equity ratio of 3.41. Cencora, Inc. has a 12 month low of $171.65 and a 12 month high of $246.75.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, May 1st. The company reported $3.80 EPS for the quarter, topping analysts’ consensus estimates of $3.65 by $0.15. The company had revenue of $68.41 billion for the quarter, compared to analyst estimates of $70.60 billion. Cencora had a return on equity of 268.67% and a net margin of 0.67%. The firm’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the firm earned $3.50 earnings per share. On average, analysts anticipate that Cencora, Inc. will post 13.44 EPS for the current year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, May 24th. Stockholders of record on Friday, May 10th were given a dividend of $0.51 per share. This represents a $2.04 annualized dividend and a dividend yield of 0.92%. The ex-dividend date was Thursday, May 9th. Cencora’s dividend payout ratio (DPR) is presently 22.32%.

Insider Transactions at Cencora

In related news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the business’s stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $215.12, for a total value of $399,991,976.80. Following the transaction, the insider now owns 24,418,171 shares in the company, valued at $5,252,836,945.52. The transaction was disclosed in a document filed with the SEC, which is available through this link. In related news, major shareholder Walgreens Boots Alliance, Inc. sold 1,859,390 shares of the business’s stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $215.12, for a total transaction of $399,991,976.80. Following the transaction, the insider now owns 24,418,171 shares in the company, valued at approximately $5,252,836,945.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Dermot Mark Durcan purchased 500 shares of the firm’s stock in a transaction on Friday, May 24th. The stock was bought at an average cost of $218.58 per share, with a total value of $109,290.00. Following the completion of the purchase, the director now owns 21,876 shares of the company’s stock, valued at approximately $4,781,656.08. The disclosure for this purchase can be found here. Insiders sold a total of 1,956,675 shares of company stock worth $422,352,056 over the last three months. 15.80% of the stock is owned by company insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.